Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(23):1740-1742; doi:10.1093/jnci/96.23.1740
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Randal, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Randal, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

NEWS

License to Test Cancer Vaccines in U.S. a Victory for Cuban Biotechnology

Judith Randal

The first 10% of the full text of this article appears below.

Although the International Symposia on Coma and Death, a quadrennial event in Havana since 1992, is always held during a U.S. presidential election year, American scientists and clinicians have always been able to attend—until this year. U.S. citizens must have a license from the Office of Foreign Assets Control (OFAC, a part of the Treasury Department) to legally travel to Cuba, and all of the Americans who had hoped to go to the March 2004 meeting had their applications turned down.

Despite that and further measures tightening the decades-old U.S. trade embargo against Cuba, CancerVax, a Carlsbad, Calif., biotechnology firm, fared better with the OFAC. It had long sought the agency's permission to license three experimental cancer vaccines from the Cuban research institute that developed and patented them, and permission was . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?